Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.44 |
| ▸ | CFB | P00751 | 7/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31203766 | 0.79 | CFB (0.33) | CFBSCN10APRCPCSNK1A1CSNK1D | |
| SCHEMBL29224679 | 0.75 | SCN10A (0.46) | CFBSCN10APRCPCSNK1A1CSNK1D | |
| Trifluoroacetic Acid SCHEMBL5100346 | 0.74 | SCN10A (0.45) | CFBSCN10APRCP | |
| SCHEMBL13119215 | 0.74 | KDM4E (0.53) | CFBSCN10ACSNK1A1CSNK1DGSK3B | |
| SCHEMBL30323027 | 0.74 | CFB (0.33) | AAK1CFBSCN10APRCP | |
| SCHEMBL30322723 | 0.73 | AAK1 (0.39) | AAK1SCN10APRCP | |
| SCHEMBL15172665 | 0.72 | SCN10A (0.56) | AAK1CFBSCN10ATAAR1 | |
| SCHEMBL15157263 | 0.72 | SCN10A (0.56) | AAK1CFBSCN10ATAAR1 | |
| SCHEMBL31203816 | 0.72 | PRCP (0.34) | AAK1SCN10APRCP | |
| SCHEMBL15172728 | 0.71 | SCN10A (0.54) | AAK1CFBSCN10ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-14 | — | — | US | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | IL17A, IL23R, IL4I1 | AAK1 3811/4885CFB 3558/4885SCN10A 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.